{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:44:15Z","timestamp":1782737055247,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","meddos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Dosimetry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.meddos.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:47:43Z","timestamp":1782733663000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective clinical implementation of the robust optimization planning technique in long-course photon radiotherapy treatment for lung cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-572X","authenticated-orcid":false,"given":"Francesco","family":"Dionisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-6163","authenticated-orcid":false,"given":"Marco","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3296-0543","authenticated-orcid":false,"given":"Erminia","family":"Infusino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Goanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-5507","authenticated-orcid":false,"given":"Anna","family":"Ianiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Soriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Widesott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.meddos.2026.06.001_bib0001","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non-small cell lung cancer: ASCO guideline rapid recommendation update","volume":"42","author":"Daly","year":"2024","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2021.03.013","article-title":"Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands","volume":"155","author":"Evers","year":"2021","journal-title":"Lung Cancer Amst. Neth"},{"issue":"20","key":"10.1016\/j.meddos.2026.06.001_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.meddos.2026.06.001_bib0004","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.meddos.2026.06.001_bib0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.meddos.2026.06.001_bib0006","article-title":"The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC","author":"Friedes","year":"2023","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"issue":"24","key":"10.1016\/j.meddos.2026.06.001_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: A secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.meddos.2026.06.001_bib0008","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1118\/1.1589492","article-title":"Limitations of a convolution method for modeling geometric uncertainties in radiation therapy. I. The effect of shift invariance","volume":"30","author":"Craig","year":"2003","journal-title":"Med. Phys"},{"key":"10.1016\/j.meddos.2026.06.001_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejmp.2017.03.009","article-title":"About the non-consistency of PTV-based prescription in lung","volume":"44","author":"Lebredonchel","year":"2017","journal-title":"Phys. Med"},{"issue":"3","key":"10.1016\/j.meddos.2026.06.001_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/acm2.12291","article-title":"Robust optimization in lung treatment plans accounting for geometric uncertainty","volume":"19","author":"Zhang","year":"2018","journal-title":"J. Appl. Clin. Med. Phys"},{"issue":"1","key":"10.1016\/j.meddos.2026.06.001_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.prro.2018.08.005","article-title":"ITV-based robust optimization for VMAT planning of stereotactic body radiation therapy of lung cancer","volume":"9","author":"Liang","year":"2019","journal-title":"Pract. Radiat. Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2340\/1651-226X.2024.40049","article-title":"Robust optimization of the gross tumor volume compared to conventional planning target volume-based planning in photon stereotactic body radiation therapy of lung tumors","volume":"63","author":"Fink","year":"2024","journal-title":"Acta Oncol. Stockh. Swed"},{"key":"10.1016\/j.meddos.2026.06.001_bib0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2019.08.005","article-title":"Practical robustness evaluation in radiotherapy: A photon and proton-proof alternative to PTV-based plan evaluation","volume":"141","author":"Korevaar","year":"2019","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"issue":"1","key":"10.1016\/j.meddos.2026.06.001_bib0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","article-title":"Errors and margins in radiotherapy","volume":"14","author":"van Herk","year":"2004","journal-title":"Semin. Radiat. Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0015","unstructured":"rsl-d-rs-12a-ifu-en-1.1-2023-03-28-raystation-12a-instructions-for-use.pdf. Accessed July 2025. Available at: https:\/\/www.raysearchlabs.com\/siteassets\/raystation-landing-page\/rsl-d-rs-12a-ifu-en-1.1-2023-03-28-raystation-12a-instructions-for-use.pdf"},{"issue":"5","key":"10.1016\/j.meddos.2026.06.001_bib0016","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/0284186X.2013.820341","article-title":"Towards individualized dose constraints: adjusting the QUANTEC radiation pneumonitis model for clinical risk factors","volume":"53","author":"Appelt","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2019.09.005","article-title":"Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer","volume":"152","author":"Defraene","year":"2020","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"issue":"2","key":"10.1016\/j.meddos.2026.06.001_bib0018","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2005.03.021","article-title":"Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy","volume":"75","author":"Belderbos","year":"2005","journal-title":"RadiOther. Oncol"},{"issue":"21","key":"10.1016\/j.meddos.2026.06.001_bib0019","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.meddos.2026.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-Year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.meddos.2026.06.001_bib0021","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.meddos.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without Cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0023","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"key":"10.1016\/j.meddos.2026.06.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110365","article-title":"Robustness evaluation of pencil beam scanning proton therapy treatment planning: A systematic review","volume":"197","author":"Sterpin","year":"2024","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol"},{"issue":"22","key":"10.1016\/j.meddos.2026.06.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aae659","article-title":"Robust radiotherapy planning","volume":"63","author":"Unkelbach","year":"2018","journal-title":"Phys. Med. Biol"},{"issue":"1","key":"10.1016\/j.meddos.2026.06.001_bib0026","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): An open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.meddos.2026.06.001_bib0027","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: The phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Medical Dosimetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095839472600049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095839472600049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:47:53Z","timestamp":1782733673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095839472600049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S095839472600049X"],"URL":"https:\/\/doi.org\/10.1016\/j.meddos.2026.06.001","relation":{},"ISSN":["0958-3947"],"issn-type":[{"value":"0958-3947","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective clinical implementation of the robust optimization planning technique in long-course photon radiotherapy treatment for lung cancer","name":"articletitle","label":"Article Title"},{"value":"Medical Dosimetry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meddos.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}